SCHEMBL6234425

SCHEMBL6234425

CC(C)CCn1c(=O)c(C2=NS(=O)(=O)c3ccccc3N2)c(O)c2cc(NC(=O)c3ccc([N+](=O)[O-])cc3)ccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CYP2C9 P11712 3/20 0.51
NR1I2 O75469 1/20 0.51
MAPT P10636 6/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.39
TP53 P04637 1/20 0.38
CASP3 P42574 2/20 0.37
CASP2 P42575 1/20 0.37
CASP7 P55210 1/20 0.37
CASP6 P55212 1/20 0.37
CASP8 Q14790 1/20 0.37
STK17B O94768 1/20 0.37
STK17A Q9UEE5 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
LMNA P02545 1/20 0.37
KDR P35968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6231895 0.92 MAPK1 (0.58) MAPK1HSD17B10CYP2C9NR1I2MAPT
SCHEMBL6267540 0.90 CYP2C9 (0.61) MAPK1HSD17B10CYP2C9NR1I2MAPT
SCHEMBL6239211 0.89 MAPK1 (0.54) MAPK1HSD17B10CYP2C9NR1I2MAPT
SCHEMBL6233742 0.88 MAPK1 (0.62) MAPK1HSD17B10CYP2C9NR1I2MAPT
SCHEMBL6234807 0.86 MAPK1 (0.61) MAPK1HSD17B10CYP2C9NR1I2MAPT
SCHEMBL6241366 0.86 MAPK1 (0.54) MAPK1HSD17B10CYP2C9NR1I2KMT2A
SCHEMBL6239797 0.86 CYP2C9 (0.59) MAPK1HSD17B10CYP2C9NR1I2MAPT
SCHEMBL6210017 0.86 MAPT (0.48) MAPTKMT2AMEN1L3MBTL1TP53
SCHEMBL6242212 0.85 MAPK1 (0.53) MAPK1HSD17B10CYP2C9NR1I2MAPT
SCHEMBL6230351 0.85 MAPK1 (0.59) MAPK1HSD17B10CYP2C9NR1I2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1401443-A4 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORP (US) 2005-10-26 EP claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US claimed
EP-1401443-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2004-03-31 EP claimed
WO-2002098424-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2002-12-12 WO claimed
US-20040147739-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147739-A1 Novel anti-infectives RPL5, RPL7, RPL35 MAPK1 3699/4885HSD17B10 1428/4885CYP2C9 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.